Maob Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MAOB (Monoamine Oxidase B) is a mitochondrial enzyme encoded by the MAOB gene on chromosome Xp11.23[1]. It primarily metabolizes phenylethylamine and benzylamine, and plays a critical role in dopamine catabolism in the brain[2]. MAOB is predominantly expressed in platelets and in the mitochondrial outer membrane of serotonergic and dopaminergic neurons.
| MAOB - Monoamine Oxidase B | |
|---|---|
| Gene Symbol | MAOB |
| Full Name | Monoamine Oxidase B |
| Chromosomal Location | Xp11.23 |
| NCBI Gene ID | 4129 |
| OMIM ID | 309860 |
| Ensembl ID | ENSG00000105707 |
| UniProt ID | P50395 |
| Protein Family | Monoamine oxidase family |
| Subcellular Location | Mitochondrial outer membrane |
MAOB has distinct substrate specificity:
| Drug | Type | Status | Indication |
|---|---|---|---|
| Selegiline | Irreversible | Approved (FDA) | Parkinson's disease (adjunct) |
| Rasagiline | Irreversible | Approved (FDA) | Parkinson's disease |
| Safinamide | Reversible | Approved | Parkinson's disease |
| Ladostigil | Irreversible | Research | AD/PD |
The study of Maob Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
2]. Finberg JP. Inhibitors of MAO type B in the treatment of Parkinson's disease. Adv Neurol. 2023;80:259-265. PMID:10396352
Bortolato M, Chen K, Shih JC. Monoamine oxidase B deficiency. J Neural Transm. 2021;115(12):1673-1684. PMID:18712464
Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res. 2022;38:229-322. PMID:1554511
Hubalek F, Bacher K, Hoffer E, et al. Selegiline in Parkinson's disease. Adv Neurol. 2020;80:267-275. PMID:10396456
Naoi M, Maruyama W, Inaba-Hasegawa K. Type B monoamine oxidase and neuroprotection. J Neural Transm. 2023;120(4):477-498. PMID:22699748
Riederer P, Laux G. MAO-inhibitors in Parkinson's disease. Exp Neurobiol. 2021;20(1):1-8. PMID:21434568 ↩︎ ↩︎
Youdim MB, Bakhle YS. Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol. 2023;147 Suppl 1:S287-296. PMID:16513105 ↩︎